Louisiana State Employees Retirement System Invests $1.27 Million in Catalyst Pharmaceuticals, Inc. $CPRX

Louisiana State Employees Retirement System bought a new stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 51,200 shares of the biopharmaceutical company’s stock, valued at approximately $1,268,000.

Several other institutional investors also recently bought and sold shares of the stock. Advisory Services Network LLC bought a new position in Catalyst Pharmaceuticals during the 3rd quarter worth approximately $39,000. Quarry LP bought a new stake in Catalyst Pharmaceuticals in the third quarter valued at approximately $40,000. Clearstead Advisors LLC lifted its position in Catalyst Pharmaceuticals by 192.9% in the fourth quarter. Clearstead Advisors LLC now owns 1,772 shares of the biopharmaceutical company’s stock valued at $41,000 after purchasing an additional 1,167 shares during the last quarter. Smartleaf Asset Management LLC boosted its stake in shares of Catalyst Pharmaceuticals by 55.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,764 shares of the biopharmaceutical company’s stock valued at $41,000 after purchasing an additional 630 shares during the period. Finally, Financial Life Planners purchased a new stake in shares of Catalyst Pharmaceuticals during the third quarter valued at approximately $42,000. 79.22% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on CPRX. Truist Financial upgraded shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, March 25th. Weiss Ratings raised shares of Catalyst Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, June 3rd. Citigroup lowered shares of Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price target for the stock from $35.00 to $31.50 in a report on Friday, May 8th. Oppenheimer cut shares of Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 7th. Finally, Cantor Fitzgerald raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Friday, March 27th. Two investment analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $32.00.

Catalyst Pharmaceuticals Stock Performance

Shares of CPRX stock opened at $31.45 on Friday. The firm has a market cap of $3.85 billion, a P/E ratio of 18.07, a P/E/G ratio of 0.96 and a beta of 0.74. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $19.05 and a fifty-two week high of $32.56. The business’s 50 day moving average price is $30.93 and its 200-day moving average price is $26.50.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).